T-lymphocyte surface antigens and receptors

T-lymphocyte surface antigens and receptors represent a broad category of proteins expressed on T-cells that are essential for immune system function and regulation (Janeway et al., 2001). This group includes the T-cell receptor (TCR) complex, which recognizes antigens presented by MHC molecules, and various co-receptors and accessory molecules such as CD3, CD4, and CD8 (NCBI, 2023). It also encompasses immune checkpoint receptors like PD-1 and CTLA-4, which serve as critical regulators of immune homeostasis and self-tolerance (Pardoll, 2012). These molecules are central to the development of many diseases; for instance, dysregulation of T-cell signaling is a hallmark of autoimmune disorders, while tumor-induced suppression of these receptors allows for cancer progression (StatPearls, 2023). Consequently, these surface proteins are major therapeutic targets, with drugs like pembrolizumab (targeting PD-1) and ipilimumab (targeting CTLA-4) revolutionizing oncology, and others like muromonab-CD3 used for immunosuppression (PubChem, 2024). Because this term refers to a diverse collection of proteins rather than a single molecule, it is considered a broad target class rather than a specific therapeutic target (MeSH, 2024).

Other names

T-cell surface markersT-cell antigensT-cell receptorsCD antigensCluster of differentiation antigens

Drugs targeting these molecules modulate T-cell activity through various mechanisms, including the blockade of inhibitory immune checkpoints (e.g., PD-1, CTLA-4), the inhibition of co-stimulatory pathways (e.g., CD28), or the direct depletion of T-cell populations (e.g., CD52) (Pardoll, 2012; PubChem, 2024).